The 2026 American Society of Clinical Oncology (ASCO) annual meeting is quickly approaching. From May 29 through June 2, in Chicago, Illinois, the 2026 ASCO Annual Meeting features groundbreaking research presentations, networking opportunities, and more. For five days, attendees can experience sessions featuring global leaders in oncology discussing the key developments shaping the future of the field.

Today, we are previewing sessions on lung cancer topics that attendees can look forward to experiencing. Dates and times are accurate as of April 28, 2026. For a complete look at the following sessions, along with all the other sessions currently scheduled, visit the official 2026 ASCO Annual Meeting program guide.

Lung Cancer Sessions at the 2026 ASCO Annual Meeting

Friday, May 29

  • Lung Cancer – Non-Small Metastatic
    • 1:00 PM – 4:00 PM
    • Description: This is an oral abstract session that includes discussions on sunvozertinib monotherapy versus platinum-based chemotherapy, managing asymptomatic brain metastases in oncogene-mutated NSCLC, and more.
  • State-of-the-Art Updates for Incorporating Precision Medicine Approaches into Every Stage of Lung Cancer
    • 4:30 PM – 5:45 PM
    • Description: This education session will address the evolving standards of care for patients with NSCLC, the optimal use of targeted therapies and immunotherapy, and more.

Saturday, May 30

  • Is the Juice Worth the Squeeze: Challenges in Combination Therapy for NSCLC
    • 8:00 AM – 9:30 AM
    • Description: This clinical science symposium will feature discussions on topics including EGFR and immunotherapy, elisrasib as first-line therapy for KRAS G12C mutation-positive NSCLC, and more.
  • Lung Cancer – Non-Small Cell Metastatic
    • 1:15 PM – 2:45 PM
    • Description: This rapid oral abstract session features topics including the efficacy and safety of HLX43 in patients with advanced NSCLC, updates on multiple clinical trial results, and more.
  • One Patient, Many Pathways: Management Options in ALK-Positive, NSCLC from Early Stage to Advanced Disease
    • 3:00 PM – 4:15 PM
    • Description: This case-based panel will discuss the disease trajectory of a patient with ALK-positive NSCLC. Attendees will hear perspectives from the surgical oncologist, radiation oncologist, and medical oncologist.
  • Lung Cancer Screening and Prevention: Beyond Conventional Strategies in a Rapidly Changing Global Milieu
    • 4:45 PM – 6:00 PM
    • Description: This session will touch on topics including the transition from tobacco smoking to vaping, the overall increase in environmental pollutants particularly in low/middle-income countries, and more.

Sunday, May 31

  • It’s 2026: Updates in Small Cell Lung Cancer – No Longer Too Small to Ignore
    • 8:00 AM – 9:15 AM
    • Description: This education session will feature discussions on topics including future directions for small-cell lung cancer regarding emerging therapies and sequencing strategies, systemic therapy for small-cell lung cancer including standard of care and recent therapeutic advances, and more.
  • Lung Cancer – Non-Small Cell Metastatic
    • 9:00 AM – 12:00 PM
    • Description: Poster session.
  • Lung Cancer – Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
    • 9:00 AM – 12:00 PM
    • Description: Poster session.
  • Lung Cancer – Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
    • 4:30 PM – 6:00 PM
    • Description: This rapid oral abstract session features discussions on topics including complex segmentectomy versus lobectomy in small-sized peripheral non-small cell lung cancer, perioperative toripalimab in NSCLC, and more.

Monday, June 1

  • When Less is More: Balancing Cost, Toxicity, and Efficacy for Treatment of Lung Cancer in an Era of Sequencing and Combination Therapies
    • 11:30 AM – 12:45 PM
    • Description: This education session features discussion on the availability of targeted and immunotherapy agents for patients with lung cancer in low-and-middle income countries, and reducing the financial burden of treatment.
  • Lung Cancer – Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
    • 1:15 PM – 4:15 PM
    • Description: This oral abstracts session features topics including air quality and stage of lung cancer diagnosis across the United States, clinical trial updates, and more.
  • Treatment Decisions After Neoadjuvant Therapy for NSCLC: Should Further Adjuvant Therapy Be Administered?
    • 4:45 PM – 6:00 PM
    • Description: This session focuses on topics including perioperative immunotherapy, neoadjuvant-only immunotherapy, surgical considerations in the integration of neoadjuvant and perioperative systemic therapies, and more. 

Sign up for alerts and stay informed on the latest clinical guidelines and guideline updates.